[Vulvovaginal candidiasis and sensitivity of pathogens to antimycotics].
OBJECTIVE
Analysis of the prevalence and species representation of pathogenic yeasts in patients with vulvovaginal candidiasis. Determination of in vitro susceptibility of yeast isolates to clinically used antimycotic agents.


METHODS
A retrospective clinical study of patients with positive vaginal cultures for the presence of pathogenic yeast species.


METHODS
I. gynekologicko-pôrodnícka klinika LF UK a FN, Zochova 7,811 03 Bratislava, Slovenská republika.


METHODS
Identification of yeast pathogens on the chromogenic medium CHROMagar CANDIDA and with API-CANDIDA identification system. In vitro susceptibility assays of clinical yeast isolates to antifungal agents using the plate dilution method, NCCLS method and ATB-FUNGUS test system.


RESULTS
The highest prevalence of vulvovaginal candidasis was found in women aged between 20-30 years. Candida albicans was the most commonly identified species of pathogenic yeasts (87.4%). Of the non-albicans species, C. glabrata (6.3%) was the most prevalent species. C. glabrata and C. krusei clinical isolates were found to be generally less susceptible to several antifungals in vitro as compared to C. albicans strains. A minimal number of resistant yeast isolates was observed for econazole, clotrimazole and nystatin. A relatively high number of resistant strains was observed for some other azole antifungals (miconazole, ketoconazole, itraconazole, fluconazole).


CONCLUSIONS
A successful treatment of vaginal mycotic infections requires the results of the microbiological analyses. They will bring evidence to a physician of the presence and fate of the pathogen, of its sensitivity to antifungals, both of which are essential for the rational and successful therapy of Candida vaginitis.
Sojáková
M
M
Gynekologicko-pôrodnícka klinika LFUK a FN, Zochova 7, 811 03 Bratislava.
Liptajová
D
D
Simoncicová
M
M
Borovský
M
M
Subík
J
J
D000328:Adult; D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002181:Candidiasis, Vulvovaginal / Q000382:microbiology*; D025141:Drug Resistance, Fungal; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D012189:Retrospective Studies
D000935:Antifungal Agents
Vulvovaginálna kandidóza a citlivost patogénov na antimykotiká.